rethinkPeptides Search
Menu
Study breakdown

DPP-4 Inhibitor Sitagliptin Doesn't Reduce Substance P Skin Inflammation in Humans

evidence
The takeaway

Single-dose sitagliptin (DPP-4 inhibitor) did not modulate substance P-induced skin inflammation in healthy volunteers, despite DPP-4 degrading substance P — acute dosing may be insufficient for anti-inflammatory effects.

Key finding

Single-dose sitagliptin (DPP-4 inhibitor) did not modulate substance P-induced skin inflammation in healthy volunteers, despite DPP-4 degrading substa

What the researchers found

Single-dose sitagliptin (DPP-4 inhibitor) did not modulate substance P-induced skin inflammation in healthy volunteers, despite DPP-4 degrading substance P — acute dosing may be insufficient for anti-inflammatory effects.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2011.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
DPP-4 Inhibitor Sitagliptin Doesn't Reduce Substance P Skin Inflammation in Humans
What was found?
Single-dose sitagliptin (DPP-4 inhibitor) did not modulate substance P-induced skin inflammation in healthy volunteers, despite DPP-4 degrading substance P — acute dosing may be insufficient for anti-inflammatory effects.

Read the original research

Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.

Biological chemistry, 392(3), 217-21

Citation

Grouzmann, Eric; Bigliardi, Paul; Appenzeller, Monique; Pannatier, André; Buclin, Thierry. (2011). Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.. Biological chemistry, 392(3), 217-21. https://doi.org/10.1515/BC.2011.003